Use when targeting The Lancet Diabetes & Endocrinology or deciding whether a diabetes, endocrine, or metabolic study fits this venue. Encodes the journal's fit, the major-trial and population-research evidence bar, reporting-guideline and registration requirements, Lancet specialty house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.
SkillScore88Maintained
Automatic
◆Clinical / Healthcare pack
Last verified 9/1/2026
What it changes
Passed 22 of 25 test cases with the skill, and 16 of 25 without it.
Without skill64%
With skill88%
Checks it passed that the model alone missed
Rates the journal fit as Low.
Formats the output using bracketed key lines starting with [Fit].
Formats the response using bracketed key lines starting with [Fit].
and 4 more in the full report
6 fixed16 passed either way3 still failing0 broke
Pass-rate lift
+24 pp
Tokens
+43%
Agent turns
0%
Response time
-28%
Model gemini-3.6-flashMeasured 9/1/2026v122 of 25 cases passed with skill
Tokens, turns and time describe resource use, not a dollar price.
See it in action
One of 6 test cases the skill fixed. Same model, same prompt, with and without the skill.
1 of 6
Prompt
We described surgical outcomes in a retrospective case series of 12 patients with Cushing's disease treated at our local clinic. Evaluate suitability for target journal The Lancet Diabetes & Endocrinology using bracketed fields ([Fit], [Target], [Specialty tags], [Study design / reporting guideline], [Method/evidence], [Top risk], [Official items to re-check], [Re-route suggestion]).
What was checked, without and with the skill
Checked
Without skill
With skill
Rates the journal fit as Low.
Passed
Passed
Suggests Journal of Clinical Endocrinology & Metabolism as a re-route option.
Missed
Passed
case-21 · gemini-3.6-flash · 9/1/2026 · answers are capped and redacted
What's inside
The instructions your model reads when the skill loads.
SKILL.md127 linessingle file
The Lancet Diabetes & Endocrinology (the-lancet-diabetes-and-endocrinology)
Journal positioning
The Lancet Diabetes & Endocrinology is a Lancet specialty journal for high-impact
clinical and population research across diabetes, obesity, endocrine, and metabolic
medicine — type 1 and type 2 diabetes, obesity and metabolic disease, thyroid,
adrenal, pituitary, bone and mineral, and reproductive endocrinology. It favors
major randomized trials, large prospective cohorts, and population/epidemiological
analyses with clear international clinical or policy consequence, with a strong
emphasis on rigorous design, hard or patient-important outcomes, and generalizable
populations. Small single-center endocrine series, mechanistic/basic-science work
without a clinical endpoint, and routine biomarker-association studies are a weak fit
and belong in a broad clinical-endocrinology or basic-science venue. This skill is a
fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and
does not replace the journal's current instructions for authors. Before submitting,
re-check the live The Lancet Diabetes & Endocrinology author instructions.
When to trigger
The author names The Lancet Diabetes & Endocrinology for a diabetes, endocrine, or
metabolic clinical/population study and wants a fit/framing check.
A trial or large cohort must be re-framed around an international, practice-changing
diabetes or endocrine question.
The author is choosing between The Lancet Diabetes & Endocrinology, the Journal of
Clinical Endocrinology & Metabolism, Diabetologia, and general medicine.
The author needs the journal's reporting-guideline, registration, and desk-reject
expectations for metabolic/endocrine evidence.
Scope & topic fit
Randomized trials in diabetes pharmacotherapy, glucose-lowering and cardiovascular-/
renal-outcome trials, and obesity/metabolic interventions.
Large prospective cohorts and high-quality observational studies on diabetes/obesity
burden, complications, prognosis, or treatment effect at scale.
Endocrine trials and cohorts (thyroid, adrenal, pituitary, bone/mineral, reproductive)
with patient-important outcomes.
Population, epidemiological, and health-policy studies on metabolic disease with
international or equity relevance.
Pragmatic, implementation, and prevention trials, and well-powered diagnostic studies,